---
schema_version: "secwatch.filing_event.v1"
accession: "0001662579-23-000040"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:49:33.887934+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Reports Q4 and Full Year 2022 Financial Results with Net Loss of $128.2M and Cash Runway to End of 2024

## Summary
- Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.
- Net loss for 2022 was $128.2M ($2.62 per share) compared to $83.9M ($1.82 per share) in 2021, driven by increased R&D and G&A expenses.
- Cash, cash equivalents and marketable securities totaled $337.1M as of Dec 31, 2022, expected to fund operations through end of 2024.
- Phase 1 dose escalation data for CFT7455 (multiple myeloma) and CFT8634 (synovial sarcoma) expected in second half of 2023.
- IND submission for CFT8919 (EGFR L858R degrader) on track for first half of 2023; CFT1946 Phase 1/2 trial dosing first patient in January 2023.

## SEC filing metadata
- accession: 0001662579-23-000040
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/0001662579-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/cccc-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662579-23-000040
- JSON: https://secwatch.observer/filing/0001662579-23-000040.json
- Plain text: https://secwatch.observer/filing/0001662579-23-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.